Introduction
============

Open-angle glaucoma is estimated to affect more than 2 million individuals in the United States according to a meta-analysis of recent population-based studies in the United States, Australia, and Europe ([@b59-co-1-225]). Owing to the rapid aging of the US population, this number is expected to increase to more than 3 million by 2020 ([@b59-co-1-225]). The definition of glaucoma has changed considerably over the past several decades. The disease is no longer defined as elevated intraocular pressure (IOP) but rather a disorder consisting of characteristic optic nerve head and visual field abnormalities ([@b1-co-1-225]). Major risk factors for the development of glaucomatous optic nerve damage include the level of IOP ([@b26-co-1-225]; [@b13-co-1-225]; [@b56-co-1-225]; [@b57-co-1-225]), increasing age ([@b3-co-1-225]), black race ([@b60-co-1-225]), positive finding for the condition in the family history ([@b29-co-1-225]), and thin central corneal thickness ([@b22-co-1-225]). However, IOP remains the only risk factor readily amenable to therapy. Therefore, almost all currently used strategies for the treatment of glaucoma are aimed at lowering or preventing a rise in IOP ([@b35-co-1-225]).

The goal of glaucoma treatment is to improve quality of life through reduction of IOP to preserve visual function. In the process of IOP reduction, an ideal medication should have a schedule that is simple to follow, be least interrupting with a patient's life, highly tolerable and affordable. However, medical treatment of glaucoma has associated side effects, complications, and costs ([@b35-co-1-225]). Prostaglandins (PGs), as a newer class of IOP-reducing agents, have gained tremendous popularity in management of glaucoma. This review is to examine the position of bimatoprost, a member of the PGs, in glaucoma medical management.

Prostaglandins in general
=========================

Prostaglandins (PGs) are biologically active derivatives of arachidonic acid with diverse local responses that are tissue dependent. Arachidonic acid is bound to phospholipids in the membranes of most mammalian cells. The release of arachidonic acid is catalyzed by the enzyme phospholipase A~2~, and arachidonic acids are then converted into PGs by cyclooxygenase and PG synthetase.

PGs are the most potent ocular hypotensive agents yet discovered. Multiple prostanoid receptors (eg, DP, EP~1~ to EP~4~, FP, IP, and TP) have been identified based on studies using molecular biologic, second-messenger, radio-ligand binding, and functional techniques ([@b12-co-1-225]). In particular, the FP receptor mediates little or no nociceptive response, plays little or no role in regulation of vessel tone and capillary permeability, and is responsible for little or no smooth muscle contraction of the bronchioles. PGF~2α~ became the PG prototype in the development of PGs for glaucoma treatment. In a human study of 18 nonglaucomatous volunteers, IOP was significantly reduced through a 24-hour period after administration of PGF~2α~ ([@b21-co-1-225]). However, it was associated with a high incidence of adverse effects including marked conjunctival hyperemia, ocular irritation, foreign-body sensation, and headache. As a result of intense effort to modify the chemical structure of PGF~2α~ to develop a compound that could reduce IOP while minimizing the incidence of side effects, four agents in this class of topical glaucoma drops are currently commercially available. They include latanoprost, unoprostone, travoprost, and bimatoprost.

The primary mechanism of action of PGs is believed to reduce IOP by increasing uveoscleral outflow. This is in contrast to other classes of antiglaucoma medications, which act by increasing aqueous humor outflow via the trabecular meshwork or by inhibiting aqueous production. Although the exact mechanisms are still not entirely clear, it appears that PGs facilitates the uveoscleral pathway in the ciliary muscle by reducing the extracellular matrix in the spaces between and within the ciliary muscle fibers ([@b62-co-1-225]; [@b51-co-1-225]). Activation of FP and EP~2~ receptors stimulates several intracellular second messenger mechanisms ([@b39-co-1-225]; [@b69-co-1-225]), which are thought to activate the biosynthesis of matrix metalloproteinases (MMPs), a family of neutral proteinases that have a lytic effect on extracellular matrix molecules.

Bimatoprost
===========

Bimatoprost (Lumigan^®^ 0.03%; Allergan, Irvine, CA, USA) is a synthetic PG. But unlike the prostaglandin F~2α~ analogs latanoprost, travoprost, and unoprostone, bimatoprost has an ethyl amide rather than an isopropyl ester at the C-1 carbon of the alpha chain. Bimatoprost has been proposed to be pharmacologically similar to a newly discovered class of fatty acid amides otherwise known as "prostamides" ([@b67-co-1-225], [@b68-co-1-225]). There is some evidence suggesting that long-term therapy with bimatoprost increases both pressure-dependent trabecular outflow and pressure-independent uveoscleral outflow via remodeling of extracellular matrix in the trabecular meshwork and ciliary muscle, respectively ([@b6-co-1-225]; [@b7-co-1-225]). It has been proposed that bimatoprost does not require hydrolysis to a free fatty acid to stimulate prostaglandin FP receptors and the pharmacological activities of bimatoprost are postulated to be mediated by a novel receptor that is different from prostaglandin receptors ([@b67-co-1-225]). However, such a receptor has not yet been identified. Whether bimatoprost is a pro-drug that is hydrolyzed to an active fatty acid for its hypotensive activity remains controversial. Although there are experiments demonstrating bimatoprost hydrolysis occurs in human ocular tissue, the rate of hydrolysis is either very slow or occurs in the presence of high concentrations of bimatoprost ([@b42-co-1-225]; [@b14-co-1-225]; [@b24-co-1-225]). In a masked vehicle-controlled study to determine the level of bimatoprost free acid in eyes treated with bimatoprost 0.03% before cataract surgery, aqueous concentrations of the free acid of bimatoprost were 22.0 ± 7.0 nmol and 7.0 ± 4.6 nmol at 2 and 12 hours after the last dose of bimatoprost, respectively ([@b8-co-1-225]). This concentration is about one-fifth the concentration of the free acid of latanoprost in the aqueous humor, but the free acid of bimatoprost has been shown to be 3--10 times more potent at the FP receptor than the free acid of latanoprost ([@b52-co-1-225]).

Efficacy
--------

Dose-response and dose-frequency studies in patients with elevated IOP have demonstrated that the most effective regimen is a once-daily dosage of bimatoprost 0.03% ([@b34-co-1-225]). Twice-daily administration was found to confer no additional efficacy and in some studies was less effective than once-daily administration ([@b5-co-1-225]; [@b34-co-1-225]; Sherwood et al 2003). Mean reductions in IOP 12 hours after administration of bimatoptost 0.03% ranged from 6.8 to 9.2 mmHg in randomized clinical trials, with reductions in IOP maintained throughout the 24-hour dosage interval and maintained for up to 1 year ([@b5-co-1-225]; [@b17-co-1-225]; [@b20-co-1-225]; [@b34-co-1-225]; Sherwood et al 2003). Bimatoprost 0.3% once-daily administration produced significantly greater reductions in IOP of about 2--4 mmHg than timolol 0.5% given twice daily, and a significantly higher percentage of patients achieved a target IOP of ≤17 mmHg with bimatoprost than with timolol treatment ([@b5-co-1-225]; [@b34-co-1-225]; Sherwood et al 2003). The combination of dorzolamide 2%/timolol 0.5% was compared with bimatoprost 0.03% in a 3-month randomized, single-blinded trial involving 177 patients with ocular hypertension or glaucoma inadequately controlled with beta-blocker therapy. Treatment with bimatoprost 0.03% produced significantly greater mean reductions in IOP at 8 AM than treatment with dorzolamide 2%/timolol 0.5% at every visit throughout the study. Furthermore, approximately twice as many patients had an IOP of ≤16 mmHg after 3 months' treatment with bimatoprost than with dorzolamide/timolol (31% vs 14%) ([@b11-co-1-225]).

The clinical efficacy of bimatoprost 0.03% has also been compared with other topical PGs. In a meta-analysis of randomized clinical trials to estimate the IOP reduction achieved by the most frequently prescribed glaucoma drugs, including latanoprost, travoprost, and bimatoprost, IOP was reduced from baseline by 31%--33% for the peak and 28%--29% for the trough with topical PGs, and bimatoprost achieved the highest reduction of IOP at peak ([@b63-co-1-225]). In a 6-month randomized clinical trial comparing bimatoprost and latanoprost in patients with ocular hypertension or glaucoma, the mean change from baseline IOP was significantly greater for bimatoprost patients than for latanoprost patients, the percentage of patients achieving a ≥20% IOP decrease was higher with bimatoprost than with latanoprost, and more bimatoprost patients achieved a lower pressure range ([@b45-co-1-225]). However, similar differences of IOP response between the two agents was not repeated in other studies. In a small, double-blinded, phase II study (n = 64) and a 3-month investigator-masked trial, no significant difference in the IOP-lowering efficacy of the drugs was observed 12 hours post-dose at the end of the treatment periods; however, diurnal control of IOP was more consistent with bimatoprost ([@b17-co-1-225]; [@b20-co-1-225]). Although the percentage of patients achieving a target IOP of ≤17 mmHg was not significantly different between treatment groups, a significantly greater proportion of the bimatoptost-treated patients reached a target IOP of ≤15 mmHg (29% vs 14%). In a 12-week comparison of the three PGs, latanoprost, bimatoprost, and travoprost, no statistical differences were observed between the three agents in mean IOP ([@b46-co-1-225]). The conflicting findings are likely due to the similarity in efficacy between the three agents. In a recent published randomized, double-blinded, crossover comparison of bimatoprost and latanoprost, the 24-hour diurnal IOP is statistically lower with bimatoprost than latanoprost. However, the difference was small (0.5 mmHg) and may not be clinically meaningful ([@b30-co-1-225]). In a retrospective review of more than 300 patients in a health management organization that had switched from latanoprost to bimatoprost, a statistically significant mean IOP difference of 0.5 mmHg was observed favoring bimatoprost ([@b37-co-1-225]). This study also showed that approximately 13% of patients had a further IOP reduction of \>3 mmHg after switching from latanoprost to bimatoprost compared with 5% of patients had a \>3 mmHg reduction while using latanoprost before the switch ([Figures 1](#f1-co-1-225){ref-type="fig"} and [2](#f2-co-1-225){ref-type="fig"}). It is likely that bimatoprost can achieve a small but statistically greater mean IOP reduction than latanoprost, but the clinical significance is uncertain. In addition, individual responses to the different agents can be variable.

Additivity
----------

Because of its similarity with other prostaglandin agents such as latanoprost and travoprost, bimatoprost is expected to be additive to other antiglaucoma agents with different mechanisms of action, including β-blockers, selective α-agonists, carbonic anhydrase inhibitors, and parasympathomimetics. However, the additivity among the three agents (latanoprost, travoprost, bimatoprost) is inconsistent. In a study with monkey eyes with laser-induced unilateral glaucoma, the IOP effects of the bimatoprost 0.03% or travoprost 0.004% were additive to that of latanoprost 0.005%, with bimatoprost showing a greater additive response than travoprost ([@b19-co-1-225]). However, no similar finding was observed in human studies. A paradoxical IOP elevation was reported after combined therapy with latanoprost and bimatoprost ([@b25-co-1-225]). In an open label clinical trial, bimatoprost 0.03% was combined with latanoprost 0.005% in one randomly assigned eye (case eye) of each patient in phase 1, and in phase 2, bimatoprost was discontinued from the case eyes while bimatoprost was substituted for latanoprost in the fellow eye (control eye). When bimatoprost and latanoprost were used together, the mean IOP increased by 1.8 mmHg, and returned to previous values after discontinuation of bimatoprost; no mean IOP change was observed throughout the study in the control eyes ([@b16-co-1-225]).

Systemic adverse reactions
--------------------------

Systemic adverse events reported after treatment with bimatoprost 0.03% have included colds and upper respiratory tract infections occurring in approximately 10% of patients, and headaches, abnormal liver function tests, asthenia, and hirsutism. Bimatoprost 0.03% did not have any clinically significant effect on heart rate or blood pressure in patients with glaucoma or ocular hypertension in clinical trials ([@b5-co-1-225]; [@b17-co-1-225]; [@b34-co-1-225]).

Since bimatoprost is similar in structure and effects with the other topical PGs, it is important to be aware of the side effects reported with the other PGs. There is a case report of abdomincal cramps associated with travoprost confirmed by dechallenge and rechallenge procedures ([@b38-co-1-225]). Other systemic events, each with an incidence of 1% or 2%, included chest pain/angina, muscle/joint/back pain, and rash/allergic skin reaction. Angina ([@b43-co-1-225]), arterial hypertension ([@b47-co-1-225]), and tachycardia have been anecdotally reported following latanoprost use. In a randomized study, headache was more frequent in patients receiving latanoprost than in those receiving bimatoprost, although this difference did not reach statistical significance ([@b20-co-1-225]). Patients with no prior history of migraine and/or headache have reported migraine after receiving latanoprost treatment ([@b66-co-1-225]).

Bimatoprost is classified as category C according to the use-in-pregnancy ratings of the US Food and Drug Administration (FDA). Experience of bimatoprost use during pregnancy is limited. However, in an observation study of 10 pregnant women exposed to latanoprost during the first trimester, 9 women delivered normal fetuses with no malformations. One pregnancy was complicated by miscarriage, which occurred 2 weeks after treatment was ended in a 46-year-old woman, primi-gravida, who had increased reproductive risk related to her advanced age ([@b15-co-1-225]).

Local adverse reactions
-----------------------

The most common adverse event associated with bimatoprost 0.03% treatment was conjunctival hyperemia, which occurred in 42%--46% of patients ([@b5-co-1-225]; [@b20-co-1-225]; [@b53-co-1-225]). Approximately 1%--4% of patients discontinued treatment with bimatoprost 0.03% because of conjunctival hyperemia ([@b5-co-1-225]; [@b53-co-1-225]). Bimatoprost 0.03% has been reported to cause changes in the pigmentation of tissues, including pigmentation of the periocular skin and iris, and eyelash darkening. Eyelash growth has also been reported in 12.6% to 35.7% of patients during clinical trials of bimatoprost 0.03% ([@b5-co-1-225]; [@b20-co-1-225]; [@b53-co-1-225]). Significantly more conjunctival hyperemia and increased eyelash growth were reported with bimatoprost than with latanoporst, whereas headache was more frequently seen in latanoprost than bimatoprost recipients ([@b20-co-1-225]; [@b45-co-1-225]; [@b46-co-1-225]; [@b58-co-1-225]). Cystoid macular edema in patients at high risk can occur when treated with bimatoprost. There is a case report of cystoid macular edema, which developed in a patient switched from latanoprost to bimatoprost 9 months after cataract surgery ([@b9-co-1-225]).

Anterior uveitis has also been observed in approximately 1% of patients receiving latanoprost which resolves with corticosteroid therapy ([@b55-co-1-225]). Association of latanoprost and uveitis has been confirmed with a dechallenge and rechallenge method in two studies (Fechter et al 1998; [@b65-co-1-225]). Use of other PGs, including bimatoprost should be cautioned in patients with known tendency of ocular inflammatory reaction. In fact, administration of latanoprost to patients with active uveitis at the time of treatment does not appear to lower IOP ([@b55-co-1-225]; [@b50-co-1-225]). The association of PGs and ocular infection of herpes simplex virus has been documented with latanoprost. Latanoprost has been shown to worsen acute herpetic keratitis in the rabbit eye (New Zealand white (NZW) rabbit) and increase the risk of recurrences in latently infected animals ([@b28-co-1-225]). However, in the Induced Reactivation and Spontaneous Shedding HSV-1/NZW rabbit latency models, latanoprost was not found to promote ocular shedding of HSV-1 ([@b23-co-1-225]). There are case reports that herpes simplex keratitis developed after initiation of latanoprost therapy with dechallenge and rechallenge method ([@b64-co-1-225]). In one case report, 2 patients developed HSV dermatitis of the periocular skin after using latanoprost ([@b44-co-1-225]). Use of any topical PGs in patients with history of ocular herpetic infection may better be avoided.

Indications
-----------

Bimatoprost is effective in reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. It is similar in efficacy and safety profiles to another older PG, latanoprost, which has gained wider experience and demonstrated effectiveness in several glaucoma subtypes, including chronic angle closure glaucoma ([@b4-co-1-225]; [@b27-co-1-225]; [@b10-co-1-225]; [@b54-co-1-225]; [@b33-co-1-225]), pigmentary glaucoma ([@b41-co-1-225]), pseudoexfoliation glaucoma ([@b31-co-1-225], [@b32-co-1-225]), and low tension glaucoma ([@b49-co-1-225]; [@b40-co-1-225]; [@b2-co-1-225]). Because of its similarity with latanoprost, bimatoprost is expected to be effective in IOP reduction in these glaucoma subtypes. However, its effectiveness in IOP reduction in glaucoma associated with uveitis or neovascularization is probably questionable in addition to the possibility of aggravation of inflammation. Although PGs are shown to be effective in IOP reduction for chronic angle closure glaucoma, its effectiveness is unreliable if a quick reduction of IOP is desirable such as in acute angle closure attack, because of its relatively slow onset of action.

Position of bimatoprost in the management of glaucoma
-----------------------------------------------------

Therapeutic use of topical PGs in management of glaucoma has grown rapidly over the past decade, and it now surpasses nonselective β-blockers as the first choice of glaucoma medical therapy due to the excellent efficacy and systemic safety profiles as well as improved compliance with once-a-day usage. Bimatoprost is currently approved by the FDA and the EC for first-line therapy for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

There is subtle yet important distinction between the concepts of first-line versus first-choice medical therapy. Topouzis clarified that first-line treatment could be defined as a treatment that has been approved by an official regulatory body as an initial therapy to control IOP, whereas a first-choice treatment is one that a physician prefers to use as an initial IOP-lowering therapy ([@b61-co-1-225]). In the healthcare system of certain countries, a designation of first-line therapy may be a result of nonmedical decisions including the cost of medication. While first choice therapy is the result of the physician's medical judgment based on experience and medical evidence and the patient's decision ([@b61-co-1-225]). The influence of first-line concept on first-choice of medical therapy often cannot be ignored. In an ophthalmic practice environment that physicians have the freedom to choose the best topical glaucoma therapy possible for their patients, the factors of first-choice consideration include the ability of the drug to lower IOP, contra-indication and adverse effects, and treatment convenience and cost. Based on these criteria for evaluation, bimatoprost is highly effective for IOP reduction, has excellent systemic safety profiles, and is easy to use with once-daily schedule. In terms of local adverse profile, it is associated with a higher rate of conjunctival hyperemia, pigmentation of the periocular skin and iris, and eyelash darkening compared with other PGs. However, in a study of assessing the feasibility of an automatic switch of a large number of patients from latanoprost to bimatoprost in a prepaid health maintenance organization, a large majority of patients (87% based on computerized ophthalmic medication dispensing record, and 89.3% based on clinical data of one clinical facility) stay with bimatoprost after the switch ([@b37-co-1-225]). Being a newer class of antiglaucoma medications without available generic substitutes, brimatoprost is generally more expensive than other classes of antiglaucoma medications.

Decision of first-choice medical therapy should be based on an individualized approach. A good choice of medication does not necessarily equate to appropriate use of medication. Some general principles of medication use apply to bimatoprost as well. It is well recognized that responses to medical therapy vary among individual patients. Therefore, enough time should be allowed for the clinician to determine whether the patient has responded to the medications or not. Once the patient has started a new medicine, he should be monitored for adverse reactions. Commonly, some patients will experience mild side effects, such as ocular irritation or blurred vision, when first using a topical medication. Thus, a useful follow-up time interval is about 2--4 weeks to determine the clinical effectiveness of therapy and the patient's ability to tolerate the medication. Lack of compliance to medical therapy is a major hurdle for glaucoma control. In the follow-up evaluations, the patient's compliance, the correct method of instillation of the drops, the proper storage of medications, and the appropriate treatment schedule should be reviewed with the patient and family or caregiver, if present ([@b36-co-1-225]). Overall, a proactive approach taken by the prescribing physician may translate into a long-lasting patient--physician relationship and better treatment outcome.

Summary
=======

In summary, the goal of treating patients with glaucoma is to minimize any adverse impact of the disease and treatment on the patient's life. Bimatoprost, based on the efficacy, safety and ease of use, has been approved as a first-line treatment for glaucoma, and well positioned among the first-choices in glaucoma medical therapy.
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